Promising data for Carvolix's TAVIPILOT at the New York Valves 2026

Carvolix presented encouraging clinical results for its TAVIPILOT platform at New York Valves 2026. This technology, specializing in artificial intelligence-based intraoperative guidance for aortic valve positioning, demonstrated 100% procedural success with no device-related incidents. The valves were implanted with precision, and an improvement in procedural time was observed, thus reducing the need for fluoroscopy and contrast agents.

Initial results from the TAVIPILOT Robot, a robotic system designed to stabilize catheters, are also promising. The robot enabled precise catheter deployment, thus contributing to the safety and efficiency of the procedure. These advances could change the dynamics of cardiac interventions, with potential future applications already under development.